It is an extension study in patients with ITP who completed participation in RMP-ITP-III clinical trial.~The study will be conducted in three stages:~Transition visit - 1 day (transition of clinical trial participants from the RMP-ITP-III study to the RMP-ITP-III-X study);~Treatment period - minimum 26 weeks;~Follow-up period - 1 week. Patients will then be provided with the study therapy till the product market access with only safety data collection.
It is a phase III extension study to assess safety and immunogenicity of long-term therapy with GNR-069 in patients with idiopathic thrombocytopenic purpura